Cost-effectiveness of pertussis booster vaccination in the Netherlands

Vaccine

Volumn 30, Issue 50, 2012, Pages 7327-7331

  Rozenbaum, Mark H ^a   De Cao, Elisabetta ^a   Postma, Maarten J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Booster; Cost effectiveness; Dynamic model; Economics; Epidemiology; Modeling; Pertussis; Vaccination

Indexed keywords

PERTUSSIS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HEALTH CARE COST; HEALTH CARE PLANNING; HUMAN; NETHERLANDS; PERTUSSIS BOOSTER VACCINATION; PRESCHOOL CHILD; PRIORITY JOURNAL; QUALITY OF LIFE; SCHOOL CHILD; VACCINATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; INFANT; MALE; MIDDLE AGED; NETHERLANDS; PERTUSSIS VACCINE; WHOOPING COUGH; YOUNG ADULT;

EID: 84869870959     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.06.026     Document Type: Article

References (24)

1. Pertussis vaccines: WHO position paper. Wkly Epidemiol Rec 2010, 85(40):385-400.
2. Zepp F., Heininger U., Mertsola J., Bernatowska E., Guiso N., Roord J., et al. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis 2011, 11(7):557-570.
3. Lee G.M., Lett S., Schauer S., LeBaron C., Murphy T.V., Rusinak D., et al. Societal costs and morbidity of pertussis in adolescents and adults. Clin Infect Dis 2004, 39(11):1572-1580.
4. De S.G., Shadmani R., Duval B., Boulianne N., Dery P., Douville F.M., et al. Morbidity of pertussis in adolescents and adults. J Infect Dis 2000, 182(1):174-179.
5. Wood N., Quinn H.E., McIntyre P., Elliott E. Pertussis in infants: preventing deaths and hospitalisations in the very young. J Paediatr Child Health 2008, 44(4):161-165.
6. Rozenbaum M.H., De V.R., LE H.H., Postma M.J. Modelling the impact of extended vaccination strategies on the epidemiology of pertussis. Epidemiol Infect 2011, 1-12.
7. Coudeville L., Van R.A., Getsios D., Caro J.J., Crepey P., Nguyen V.H. Adult vaccination strategies for the control of pertussis in the United States: an economic evaluation including the dynamic population effects. PLoS One 2009, 4(7):e6284.
8. de Vries R., Kretzschmar M., Schellekens J.F.P., Versteegh F.G.A., Westra T.A., Roord J.J., et al. Cost-Effectiveness of adolescent pertussis vaccination for the Netherlands: using an individual-based dynamic model. PLoS One 2010, 5(10):e13392.
9. Millier A., Aballea S., Annemans L., Toumi M., Quilici S. A critical literature review of health economic evaluations in pertussis booster vaccination. Expert Rev Pharmacoecon Outcomes Res 2012, 12(1):71-94.
10. Brisson M., Edmunds W.J. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs. Med Decision Making 2006, 26(5):434-446.
11. de Melker H.E., Versteegh F.G., Schellekens J.F., Teunis P.F., Kretzschmar M. The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. J Infect 2006, 53(2):106-113.
12. Wendelboe A.M., Van R.A., Salmaso S., Englund J.A. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005, 24(5 Suppl.):S58-S61.
13. Oostenbrink J.B., Bouwmans C.A.M., Koopmanschap M.A., Rutten F.H.H. Guidelines for costing research, methods and standardized prices for economic evaluations in health care 2004, Health Care Insurance Board, Diemen, the Netherlands.
14. Rozenbaum M.H., Hoek A.J., Hak E., Postma M.J. Huge impact of assumptions on indirect effects on the cost-effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar). Vaccine 2010, 28(12):2367-2369.
15. Rozenbaum M.H., Sanders E.A., van Hoek A.J., Jansen A.G., van der Ende A., van den Dobbelsteen G., et al. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ 2010, 340:c2509.
16. Westra T.A., De V.R., Tamminga J.J., Sauboin C.J., Postma M.J. Cost-effectiveness analysis of various pertussis vaccination strategies primarily aimed at protecting infants in the Netherlands. Clin Ther 2010, 32(8):1479-1495.
17. Taranger J., Trollfors B., Bergfors E., Knutsson N., Lagergard T., Schneerson R., et al. Immunologic and epidemiologic experience of vaccination with a monocomponent pertussis toxoid vaccine. Pediatrics 2001, 108(6):E115.
18. Gustafsson L., Hallander H.O., Olin P., Reizenstein E., Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996, 334(6):349-355.
19. Trollfors B., Taranger J., Lagergard T., Sundh V., Bryla D.A., Schneerson R., et al. Immunization of children with pertussis toxoid decreases spread of pertussis within the family. Pediatr Infect Dis J 1998, 17(3):196-199.
20. Nielsen A., Larsen S.O. Epidemiology of pertussis in Denmark: the impact of herd immunity. Int J Epidemiol 1994, 23(6):1300-1308.
21. Cooper E., Fitch L., Pertussis: 1. herd immunity and vaccination coverage in St. Lucia. Lancet 1983, 2(8359):1129-1132.
22. Olin P., Gustafsson L., Barreto L., Hessel L., Mast T.C., Rie A.V., et al. Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. Vaccine 2003, 21(17-18):2015-2021.
23. Preziosi M.P., Yam A., Wassilak S.G., Chabirand L., Simaga A., Ndiaye M., et al. Epidemiology of pertussis in a West African community before and after introduction of a widespread vaccination program. Am J Epidemiol 2002, 155(10):891-896.
24. Statistics Netherlands. ; 2012 [accessed 3.2.2012]. http://statline.cbs.nl/StatWeb/publication/%3FVW=T%26DM=SLNL%26PA=7233%26D1=33%26D2=0%26D3=0%26D4=a%26HD=120203-2201%26HDR=G2,G1,G3%26STB=T.